Condition: Diffuse Large B Cell Lymphoma · Large B-cell Lymphoma · Primary Mediastinal Large B Cell Lymphoma · Sponsor: Pell Bio-Med Technology Co., Ltd.
According to health authorities guidances (FDA 2006, EMA(European Medicines Agency) 2009) for gene therapy clinical trials, observing subjects for delayed adverse events for 15 years is recommended. This purpose of this long-term follow-up study is to evaluate the safety and efficacy in patients who have ever received lentiviral-based gene-edited immune cells which are manufactured by Pell Bio-Med Technology Co. Ltd.
This description comes directly from the study's public registry record.
Cherry Lo, MSC · 886-2-8791-1789 · cherry.lo@pellbmt.com
Always discuss trial participation with your own doctor first.
| Kaohsiung Medical University Chung-Ho Memorial Hospital | Kaohsiung, Taiwan, Taiwan | Recruiting |
| National Taiwan University Hospital | Taipei, Taiwan, Taiwan | Recruiting |
| Taipei Veterans General Hospital | Taipei, Taiwan, Taiwan | Recruiting |
| Chi Mei Medical Center | Tainan, Taiwan | Recruiting |
| Taipei Medical University - Taipei Medical University Hospital | Taipei, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05377307